{
  "first_published_at": "2008-12-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087988", 
  "title": "Norfloxacin: restricted use in urinary infections", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\", \"urology-nephrology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\", \"Urology and nephrology\"]}", 
  "_document_number": 277, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "infectious-disease", 
    "urology-nephrology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Norfloxacin: restricted use in urinary infections</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: December 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The European Medicines Agency (EMA) has concluded that the oral fluoroquinolone norfloxacin (Utinor) should not be used to treat acute or chronic complicated pyelonephritis.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The European Medicines Agency (EMA) has concluded that the oral fluoroquinolone <strong>norfloxacin</strong> (Utinor) should not be used to treat acute or chronic complicated pyelonephritis. The Agency&rsquo;s Committee for Medicinal Products for Human Use concluded that this indication should be withdrawn because efficacy has not been adequately shown for this type of infection, and because the benefits of norfloxacin do not outweigh the potential risks in this indication.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Oral norfloxacin should no longer be prescribed for newly diagnosed complicated pyelonephritis</li>\r\n\t\t\t\t<li>Prescribers should review any patient taking oral norfloxacin for complicated pyelonephritis at their next scheduled visit, and should consider the need for alternative treatment if signs or symptoms of infection are persisting</li>\r\n\t\t\t</ul></div><p><strong>See also:</strong></p><p><a href=\"http://www.emea.europa.eu/pdfs/human/press/pr/38026008en.pdf\" target=\"_blank\">EMA press release</a>&nbsp;</p><p><br><em>Article citation: Drug Safety Update Dec 2008, vol 2 issue&nbsp;5: 7c.</em>&nbsp;</p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The European Medicines Agency (EMA) has concluded that the oral fluoroquinolone <strong>norfloxacin</strong> (Utinor) should not be used to treat acute or chronic complicated pyelonephritis. The Agency&#8217;s Committee for Medicinal Products for Human Use concluded that this indication should be withdrawn because efficacy has not been adequately shown for this type of infection, and because the benefits of norfloxacin do not outweigh the potential risks in this indication.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Oral norfloxacin should no longer be prescribed for newly diagnosed complicated pyelonephritis</li>\r\n\t\t\t\t<li>Prescribers should review any patient taking oral norfloxacin for complicated pyelonephritis at their next scheduled visit, and should consider the need for alternative treatment if signs or symptoms of infection are persisting</li>\r\n\t\t\t</ul></div><p><strong>See also:</strong></p><p><a href=\"http://www.emea.europa.eu/pdfs/human/press/pr/38026008en.pdf\" target=\"_blank\">EMA press release</a>&#160;</p><p><br><em>Article citation: Drug Safety Update Dec 2008, vol 2 issue&#160;5: 7c.</em>&#160;</p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-12-01", 
  "date_last_modified": "2010-09-24", 
  "_assets": [], 
  "_item_id": 277, 
  "summary": "", 
  "body": "Article date: December 2008\n\nThe European Medicines Agency (EMA) has concluded that the oral fluoroquinolone norfloxacin (Utinor) should not be used to treat acute or chronic complicated pyelonephritis. The Agency’s Committee for Medicinal Products for Human Use concluded that this indication should be withdrawn because efficacy has not been adequately shown for this type of infection, and because the benefits of norfloxacin do not outweigh the potential risks in this indication.\n\nAdvice for healthcare professionals:  \n  \n  * Oral norfloxacin should no longer be prescribed for newly diagnosed complicated pyelonephritis  \n  * Prescribers should review any patient taking oral norfloxacin for complicated pyelonephritis at their next scheduled visit, and should consider the need for alternative treatment if signs or symptoms of infection are persisting  \n  \nSee also:\n\n[EMA press release](http://www.emea.europa.eu/pdfs/human/press/pr/38026008en.pdf) \n\n  \nArticle citation: Drug Safety Update Dec 2008, vol 2 issue 5: 7c. \n"
}